BioXcel Therapeutics Inc 2026年季度报告

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filingrequirements for the past 90 days. Yes⌧No◻ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 ofRegulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit suchfiles). Yes⌧No◻ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or anemerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growthcompany” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any newor revised financial accounting standards provided pursuant to Section13(a)of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act). Yes☐No☒ Table of Contents PARTI- FINANCIAL INFORMATION Forward Looking Statements3Summary Risk Factors4Item1.Financial Statements (Unaudited)7Condensed Consolidated Balance Sheets as of March 31, 2026 and December 31, 20257Condensed Consolidated Statements of Operations for the three months ended March31, 2026 and 20258Condensed Consolidated Statements of Changes in Stockholders’ (Deficit) Equity forthe three months ended March 31, 2026 and 20259Condensed Consolidated Statements of Cash Flows for the three months ended March31, 2026 and 202510Notesto Condensed Consolidated Financial Statements11Item2.Management’s Discussion and Analysis of Financial Condition and Results ofOperations41Item3.Quantitative and Qualitative Disclosures About Market Risk68Item4.Controls and Procedures68 PARTIIOTHER INFORMATION Item1.Legal Proceedings69Item1A.Risk Factors69Item 2.Unregistered Sales of Equity Securities and Use of Proceeds136Item 3.Defaults Upon Senior Securities136Item 4.Mine Safety Disclosures136Item 5.Other Information136Item6.Exhibits137Signatures140 FORWARD-LOOKING STATEMENTS This Quarterly Report on Form10-Q (this “Quarterly Report”) contains forward-looking statementswithin the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements containedin Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of theSecurities Exchange Act of 1934, as amended (the “Exchange Act”). The words “anticipate,” “believe,”“can,” “continue,” “could,” “designed,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,”“might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” andsimilar expressions are intended to identify forward-looking statements, though not all forward-lookingstatements use these words or expressions. All statements contained in this Quarterly Report, other thanstatements of historical fact, are forward-looking statements, including, without limitation, statementsregarding: ●our ability to raise additional capital and continue as a going concern;●our sales strategy for IGALMI®;●our ability to stay listed on the Nasdaq Capital market;●compliance with covenants under our financing arrangements;●developments relating to our SERENITY and TRANQUILITY programs;●the size of our total addressable markets and related underlying estimates;●our plans relating to clinical trials and marketing applications for our product candidates;●our plans to research, develop and commercialize our current and future product candidates;●our plans to seek to enter into collaborations for the development and commercialization ofcertain product candidates;●the potential benefits of any future collaboration;●the timing of and our ability to obtain and maintain regulatory approvals for our productcandidates;●the timing of and results of discussions we have with regulators;●the rate and degree of market acceptance, clinical utility, number of prescribers and formularywins of IGALMI®and any product candidates for which we receive marketing approval;●our commercialization, marketing and manufacturing capabilities and strategy, including thepotential benefits from any advertising campaigns;●our participation in, and any potential benefits from, events, conferences, presentations andconventions;●our intellectual property position and strategy;●our estimates regarding expenses, future revenue, capital requirements and need for additionalfinancing;●potential investments in, or other s